Study Finds Key Molecule For Prostate Cancer Development

Study Finds Key Molecule For Prostate Cancer Development
Two recent studies published by a research team from the University of Hull, showed that prostate cancer patients whose tumors are positive for a molecule called Endo180, have a higher tendency to develop a more severe form of the disease. The studies, published in Molecular Cancer Research and The Journal of Pathology, respectively, showed that roughly 65% of patients with Endo180-positive tumors did not survive past 5 years of diagnosis. This was a significantly higher rate when compared to the 39% observed in men who were negative for Endo180. The team also studied the mechanism behind this phenomenon, which was tightly linked to the capacity of prostate cancer to metastasize to other sites in the body. “It’s a real Jekyll and Hyde scenario. We found that in healthy ‘non-cancerous’ prostate cells Endo180 is normally stuck to another molecule, and this pairing completely suppresses the cells from behaving dangerously. However, when we broke the two molecules apart, Endo180 completely flipped its role and actively encouraged cells to break away from each other, which is the deadly feature of those cancers that start to spread to other parts of the body”, lead author Dr. Justin Sturge, said in a news release. Furthermore, the research team also demonstrated that upon ageing, the physical alterations in prostate tissue could trigger a spontaneous switch in Endo180 activity. “We’ve not only shown that Endo180 is a strong predictive marker of disease severity in patients with prostate cancer, but we’ve also uncovered a potential new way to monitor and target the disease”, Dr. Sturge explained. “We believe this research will ultimately help pave the way to more personalised medicine for prostate cancer patients. Our findings suggest that i
Subscribe or to access all post and page content.